Characterization of Circulating Tumor Cells Captured by c-MET (CTC-MET)

Inclusion Criteria

• •Prostate cancer patients will be eligible for inclusion in this study only if all of the following criteria apply:
• •1. Histologically confirmed diagnosis of adenocarcinoma of the prostate. Small cell or neuroendocrine tumors of the prostate are also permitted.
• •2. Clinical or radiographic evidence of metastatic disease.
• •3. Castrate levels of testosterone (\<50 ng/dl)
• •4. Enrollment prior to the initiation of a new systemic therapy.
• •5. Evidence of disease progression on or following most recent therapy as evidenced by either of the following:
• •* Two consecutive PSA levels greater than the PSA nadir achieved on ADT and most recent therapy, separated by greater than one week
• •* Radiographic evidence of disease progression as defined by new bone scan lesions or growth of soft tissue/visceral metastases \>1 cm in diameter (2 cm for lymph nodes).
• •* Clinical progression of disease with cutaneous lesions or palpable lesions in absence of radiographic progression
• •6. Age \> 18 years.
• •7. Ability to understand and the willingness to sign a written informed consent document.
• •1. Histologically confirmed diagnosis of invasive renal cell carcinoma (all histologies)
• •2. Clinical or radiographic evidence of metastatic disease.
• •3. Evidence of disease progression on the current or following the most recent therapy, as defined by one of the following:
• •* A new soft tissue/visceral/lymph node/bone metastatic lesion
• •* Growth of existing soft tissue/visceral/lymph node/bone metastases as determined by the investigator
• •* Clinical progression of disease with cutaneous lesions or palpable lesions in absence of radiographic progression
• •4. For clear cell carcinoma, refractory to treatment with VEGF inhibitors as defined by progression on VEGF therapy within 1 year of starting VEGF therapy. For non-clear cell histologies, any line of systemic therapy.
• •5. Enrollment prior to the initiation of a new systemic therapy.
• •6. Age \> 18 years.
• •7. Ability to understand and the willingness to sign a written informed consent document.
• •1. Histologically confirmed diagnosis of invasive bladder transitional cell carcinoma, adenocarcinoma, squamous cell carcinoma, or small cell carcinoma.
• •2. Metastatic disease with either bone or visceral metastatic lesions, or clinically symptomatic with metastatic disease.
• •3. Progression of disease on or following the most recent treatment as evidenced by one of the following:
• •* A new soft tissue/visceral/lymph node/bone metastatic lesion
• •* Growth of existing soft tissue/visceral/lymph node/bone metastases as determined by the investigator.
• •* Clinical progression of disease with cutaneous lesions, palpable lesions, pleural effusions, or ascites in absence of radiographic progression
• •4. Enrollment prior to the initiation of a new systemic therapy.
• •5. Age \> 18 years.
• •6. Ability to understand and the willingness to sign a written informed consent document.
• •1. Histologically confirmed diagnosis of invasive gastric or distal esophageal adenocarcinoma.
• •2. Clinical or radiographic evidence of metastatic disease.
• •3. Evidence of disease progression on or following the most recent therapy, as defined by one of the following:
• •* New soft tissue/visceral/lymph node/bone metastatic lesion
• •* Growth of existing soft tissue/visceral/lymph node/bone metastases as determined by the investigator
• •* Clinical progression of disease with cutaneous lesions, palpable lesions, pleural effusions, or ascites in absence of radiographic progression
• •4. Enrollment prior to the initiation of a new systemic therapy.
• •5. Age \> 18 years.
• •6. Ability to understand and the willingness to sign a written informed consent document.
• •1. Histologically confirmed diagnosis of invasive colorectal adenocarcinoma.
• •2. Clinical or radiographic evidence of metastatic disease.
• •3. Evidence of disease progression on the current or following the most recent therapy, as defined by one of the following:
• •* New soft tissue/visceral/lymph node/bone metastatic lesion
• •* Growth of existing soft tissue/visceral/lymph node/bone metastases as determined by the investigator
• •* Clinical progression of disease with cutaneous lesions, palpable lesions, pleural effusions, or ascites in absence of radiographic progression
• •4. Enrollment prior to the initiation of a new systemic therapy.
• •5. Age \> 18 years.
• •6. Ability to understand and the willingness to sign a written informed consent document.
• •1. Histologically confirmed diagnosis of invasive pancreatic adenocarcinoma.
• •2. Clinical or radiographic evidence of metastatic disease.
• •3. Enrollment prior to the initiation of a new systemic therapy.
• •4. Age \> 18 years.
• •5. Ability to understand and the willingness to sign a written informed consent document.
• •1. Histologically confirmed diagnosis of cancer (any kind)
• •2. MET gene amplification by FISH, CISH, rtPCR, or other assay as determined by the investigator.
• •3. Clinical or radiographic evidence of metastatic disease.
• •4. Age \> 18 years.
• •5. Ability to understand and the willingness to sign a written informed consent document.
• •1. Histologically confirmed diagnosis of invasive non-small cell carcinoma of the lung (includes adenocarcinoma, squamous cell carcinoma, large cell carcinoma, adenosquamous, and carcinomas with pleomorphic, sarcomatoid, or sarcomatous elements; does not include carcinoid tumor or neuroendocrine carcinoma).
• •2. Metastatic disease with either bone or visceral metastatic lesions, or clinically symptomatic with metastatic disease.
• •3. Progression of disease on or following the most recent treatment as evidenced by one of the following:
• •* A new soft tissue/visceral/lymph node/bone metastatic lesion
• •* Growth of existing soft tissue/visceral/lymph node/bone metastases as determined by the investigator.
• •* Clinical progression of disease with cutaneous lesions or palpable lesions in absence of radiographic progression
• •4. Progression of disease either on or following treatment with an EGFR inhibitor (such as erlotinib, gefitinib, or other EGFR-targeted therapy)
• •5. Enrollment prior to the initiation of a new systemic therapy.
• •6. Age \> 18 years.
• •7. Ability to understand and the willingness to sign a written informed consent document.